S1P Modulators – PharmaLive

Pfizer’s S1P Therapy Scores Second Phase III Win in Ulcerative Colitis

Clinical Trials, Inflammatory Bowel Disease, Pfizer, R&D, S1P Modulators, Topline Data, Ulcerative Colitis

Pfizer announced positive top-line results from the company’s year-long Phase III trial of etrasimod for the treatment of ulcerative colitis (UC). Pfizer plans to pursue regulatory filings for the drug during 2022.

Celgene Submits Application to FDA for Ozanimod for the Treatment of Relapsing Forms of Multiple Sclerosis

EMA, FDA, FDA/Regulatory, Marketing Authorization Application (MAA), New Drug Application (NDA), Relapsing Multiple Sclerosis (RMS), S1P Modulators

Celgene Corporation announced that the company submitted a New Drug Application to the U.S. FDA for ozanimod for the treatment of adults with relapsing forms of multiple sclerosis (RMS).

Biogen Forges $544M Deal to Take on Celgene With a Rival Autoimmune Drug

Autoimmune Disorders, Crohn's Disease, Crohn's Disease, Drug Safety, Health, Inflammatory Bowel Disease, Licensing, Multiple Sclerosis, Multiple Sclerosis, Quarterly results, R&D, S1P Modulators, Sales, Therapeutics, Ulcerative Colitis, Ulcerative Colitis

Biogen, Inc., headquartered in Cambridge, Mass., announced today that it licensed MT-1303 from Mitsubishi Tanabe Pharma Corporation, located in Osaka, Japan. MT-1303 is being investigated in a number of autoimmune […]